John D. Imig
Professor
Also affiliated: Tulane University (1996–2003); Louisiana State University (2000); American Heart Association (2004); Naval Medical Center San Diego (1998); National Institutes of Health (2001–2004); University of Louisville (1991–1993); University of Ottawa (2000); University of Georgia (2005); The University of Melbourne (2000–2002); Ollscoil na Gaillimhe – University of Galway (2019); Vanderbilt University (2001–2002); Czech Academy of Sciences (2013); Medical College of Wisconsin (1984–2026); Charles University (2016); Florey Institute of Neuroscience and Mental Health (2002); Augusta University (2000–2009); University of Arkansas Medical Center (2025); Tulane Medical Center (1996–1997); Henry Ford Hospital (2002–2013); Augusta University Health (2000–2009); National Institute of Environmental Health Sciences (2003); Center for Vascular Biology Research (2007); Czech Academy of Sciences, Institute of Physiology (2013); Ottawa Hospital Research Institute (2000); UC Davis Comprehensive Cancer Center (2002–2013); Medical College of Wisconsin Cancer Center (2020–2025); Case Western Reserve University (2013); University of Nebraska Medical Center (2001); University of California, Davis (2002–2013); The University of Texas Southwestern Medical Center (1999–2013)
COP | College of Pharmacy
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
John D. Imig's research focuses on the physiological and pathological roles of soluble epoxide hydrolase (sEH) and its related metabolites in cardiovascular and renal diseases. His work investigates how inhibiting sEH can lower arterial blood pressure and offer protection in conditions like angiotensin II-induced hypertension and salt-sensitive hypertension. Imig has explored the involvement of epoxides and sEH in cardiovascular physiology, as well as the immune and inflammatory aspects of renal disease.
His federally funded research includes projects examining the endothelial epxoxygenase pathway, kidney injury, and blood pressure regulation, supported by grants from the NIH/National Institute of Diabetes and Digestive and Kidney Diseases. He also leads a T32 postdoctoral training grant from the NIH/National Center for Advancing Translational Sciences. Imig holds designations as an ARA Academy member and is recognized as a highly cited researcher with a substantial publication record and high citation count.
His collaborative network includes researchers from the University of Arkansas at Fayetteville and within the University of Arkansas for Medical Sciences, with whom he has co-authored numerous publications. Imig leads an active research group and maintains a lab website detailing his ongoing work.
Metrics
- h-index: 72
- Publications: 428
- Citations: 16,429
Positions
-
Professor publications 2023–2026University of Arkansas for Medical Sciences COP | College of Pharmacy Institutional directory
-
Chair and Professor publications 2023–2026University of Arkansas for Medical Sciences ORCID
Selected Publications
-
Editorial: New insights on vascular and metabolic diabetic complications (2026)
-
NF Erythroid 2-Related Factor 2 Peroxisome Proliferator-Activated Receptor-γ Crosstalk (2025)
-
EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage (2025)
-
Targeting p66Shc to restore KATP channel and renal microvascular responses in a preclinical model of diabetic nephropathy (2025)
-
Prevention of hypertension-induced renal vascular dysfunction through a p66Shc-targeted mechanism (2025)
-
591 Low kidney mass contributes to enhanced fractionated irradiation-induced renal hemodynamic dysfunction in mice (2025)
-
Synthetic Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib-Induced Cell Death (2025)
-
Hypertension: A Continuing Public Healthcare Issue (2024)
-
The Immune System in Nephrotoxicity (2024)
-
Kidney Hypoplasia Increases Kidney Injury following Reversal of Unilateral Ureteral Obstruction (2024)
-
O74 EPOXYEICOSATRIENOIC ACIDS ANALOGUE (EET-A) FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED HEART FAILURE WITH NEPHROTIC SYNDROME (2024)
-
Characterization of a new model of chemotherapy-induced heart failure with reduced ejection fraction and nephrotic syndrome in Ren-2 transgenic rats (2024)
-
Attenuation of renal injury by administration of TK-850, a dual inhibitor of TGFβR1/MAP4K4 (2024)
-
Novel compounds that target epoxyeicosanoids protect rat kidney epithelial cells in organ transplant solution during cold storage (2024)
-
Unraveling mechanisms underlying VEGF-TKI inhibitor related nephrotoxicity and protection by EET analogs: identifying key genes using RNA seq in mesangial cells (2024)
ARA Academy 2022 ARA Scholar
Dr. Imig joined UAMS in 2022 from the Medical College of Wisconsin, where he directed the Drug Discovery Center. His research addresses conditions affecting the heart, metabolism, and kidneys. He maintains active NIH funding and has published approximately 250 articles and holds six U.S. patents with additional applications pending.
Policy Impact
Recruited from the Medical College of Wisconsin with active NIH funding, approximately 250 publications, and six U.S. patents — expanding Arkansas's drug discovery capacity.
Growth Areas
['Population Health Innovations & Clinical Research']
Federal Grants 2 $701,305 total
CTSA Postdoctoral T32 at University of Arkansas for Medical Sciences
Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- Epoxyeicosanoids and Renal Vascular Function in Obesity &Hypertension NIH Principal Investigator
- Theophylline Prophylaxis during Hypothermia to Limit Neonatal Nephron Damage NIH/Nat. Inst. of Diabetes & Digestive & Kidney Diseases via Medical College of Wisconsin Principal Investigator
- Role of p66Shc in Regulation of Microvascular Reactivity of Renal Blood Vessels NIH/Nat. Heart, Lung & Blood Institute via Medical College of Wisconsin Principal Investigator
- OXYGENASE METABOLITES AND RENAL VASCULAR ACTIVITY NIH Principal Investigator
- CYTOCHROME P450 AND NO IN CONTROL OF RENAL VASCULAR TONE NIH Principal Investigator
- Eicosanoid-based Therapy for Diabetes NIH Principal Investigator
- Novel epoxide hydrolase inhibitor for stroke prevention NIH Principal Investigator
- ABI J. Imig Startup FY26 Y4 State of Arkansas Principal Investigator
- ABI C. OBrien NIH COBRE FY26 Y4 State of Arkansas Principal Investigator
Collaboration Network
Top Collaborators
- Hypertension: A Continuing Public Healthcare Issue
- Salt-sensitive hypertension after reversal of unilateral ureteral obstruction
- Kidney Injury by Unilateral Ureteral Obstruction in Mice Lacks Sex Differences
- Lack of Kidney Injury Sex Differences in Unilateral Ureter Obstructed Mice
- Lack of Kidney Injury Sex Differences in Unilateral Ureter Obstructed Mice
Showing 5 of 13 shared publications
- Kidney Injury by Unilateral Ureteral Obstruction in Mice Lacks Sex Differences
- Synthetic Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib-Induced Cell Death
- Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib Induced Cell Death
- The Immune System in Nephrotoxicity
- 591 Low kidney mass contributes to enhanced fractionated irradiation-induced renal hemodynamic dysfunction in mice
Showing 5 of 6 shared publications
- Salt-sensitive hypertension after reversal of unilateral ureteral obstruction
- Kidney Injury by Unilateral Ureteral Obstruction in Mice Lacks Sex Differences
- Dual soluble epoxide hydrolase inhibitor – farnesoid X receptor agonist interventional treatment attenuates renal inflammation and fibrosis
- 591 Low kidney mass contributes to enhanced fractionated irradiation-induced renal hemodynamic dysfunction in mice
- EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage
- Synthetic Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib-Induced Cell Death
- Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib Induced Cell Death
- Unraveling mechanisms underlying VEGF-TKI inhibitor related nephrotoxicity and protection by EET analogs: identifying key genes using RNA seq in mesangial cells
- Novel compounds that target epoxyeicosanoids protect rat kidney epithelial cells in organ transplant solution during cold storage
- Synthetic Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib-Induced Cell Death
- Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib Induced Cell Death
- Unraveling mechanisms underlying VEGF-TKI inhibitor related nephrotoxicity and protection by EET analogs: identifying key genes using RNA seq in mesangial cells
- EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage
- Synthetic Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib-Induced Cell Death
- Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib Induced Cell Death
- Unraveling mechanisms underlying VEGF-TKI inhibitor related nephrotoxicity and protection by EET analogs: identifying key genes using RNA seq in mesangial cells
- EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage
- Salt-sensitive hypertension after reversal of unilateral ureteral obstruction
- Kidney Injury by Unilateral Ureteral Obstruction in Mice Lacks Sex Differences
- Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib Induced Cell Death
- 557 Dual TGFβR1/MAP4K4 inhibitor reduces kidney injury in a mouse model of renal fibrosis.
- Attenuation of renal injury by administration of TK-850, a dual inhibitor of TGFβR1/MAP4K4
- 591 Low kidney mass contributes to enhanced fractionated irradiation-induced renal hemodynamic dysfunction in mice
- Salt-sensitive hypertension after reversal of unilateral ureteral obstruction
- Dual soluble epoxide hydrolase inhibitor – farnesoid X receptor agonist interventional treatment attenuates renal inflammation and fibrosis
- Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib Induced Cell Death
- Unraveling mechanisms underlying VEGF-TKI inhibitor related nephrotoxicity and protection by EET analogs: identifying key genes using RNA seq in mesangial cells
- Dual soluble epoxide hydrolase inhibitor – farnesoid X receptor agonist interventional treatment attenuates renal inflammation and fibrosis
- Novel compounds that target epoxyeicosanoids protect rat kidney epithelial cells in organ transplant solution during cold storage
- 557 Dual TGFβR1/MAP4K4 inhibitor reduces kidney injury in a mouse model of renal fibrosis.
- Attenuation of renal injury by administration of TK-850, a dual inhibitor of TGFβR1/MAP4K4
- 557 Dual TGFβR1/MAP4K4 inhibitor reduces kidney injury in a mouse model of renal fibrosis.
- Attenuation of renal injury by administration of TK-850, a dual inhibitor of TGFβR1/MAP4K4
- 557 Dual TGFβR1/MAP4K4 inhibitor reduces kidney injury in a mouse model of renal fibrosis.
- Attenuation of renal injury by administration of TK-850, a dual inhibitor of TGFβR1/MAP4K4
- Synthetic Epoxyeicosatrienoic Acid Mimics Protect Mesangial Cells from Sorafenib-Induced Cell Death
- Unraveling mechanisms underlying VEGF-TKI inhibitor related nephrotoxicity and protection by EET analogs: identifying key genes using RNA seq in mesangial cells
Similar Researchers
Based on overlapping research topics